Anybody in. Way of the future as far as I'm concerned. Hopefully...

Anybody in. Way of the future as far as I'm concerned. Hopefully we are all living older but a lot of us carry injuries through deterioration, inflammation etc. and someone has to come up with a solution. That's why I got into Orthocell (OCC)  and it's be very profitably and maybe PAR can start making small steps as to finding an effective treatment for BME. Been priced to perfection so it's not cheap and still years away from finishing trials  then going to market
( if successful ) so one for the bottom draw.


Paradigm is an Australian biopharmaceutical company focused on repurposing the drug, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema (BME). Paradigm is also developing PPS to treat respiratory diseases; allergic asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD).
Drug repurposing means finding new indications for old drugs. This allows Paradigm to overcome traditional drug development hurdles such as, safety data, mechanism of action and manufacturing. Thus, Paradigm is in the unique position to manage its risk profile compared to other early stage drug development companies. Risks are managed as the drug development cycle times are much shorter, development costs are significantly less and success rates are much higher.
Paradigm’s lead drug for repurposing is pentosan polysulphate sodium (PPS) which is over 60 years old. First developed in Germany in 1949 to treat blood clots, PPS has a known safety profile, a method of action that has been extensively studied. Paradigm has signed an exclusive supply agreement with the original German manufacturer of PPS bene pharmaChem.
Paradigm’s principle activity is the use of PPS to treat the large clinical indication of Bone Marrow Edema (BME). BME is a painful condition where excess fluid occurs in the bone marrow in the subchondral bone (part of the bone which is under and adjacent to the cartilage). BME is characterised by inflammation, cartilage degeneration and blood clotting within the bone.

http://paradigmbiopharma.com/product-lead-candidate/